BofA lowered the firm’s price target on Harmony Biosciences (HRMY) to $28 from $32 and keeps an Underperform rating on the shares. The firm’s lowered target mainly reflects more conservative risk-adjustment on 2028 company cash flows as it now models 25% probability of retaining Wakix cash flows in 2028 when composition of matter, key method of use and regulatory exclusivities have lapsed, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership
- Harmony Biosciences reports Q4 adjusted EPS 57c, consensus $1.07
- Harmony Biosciences backs FY26 revenue view $1B-$1.04B, consensus $1.01B
- Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank
- Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Cheat Sheet